Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Operations (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Cash from Operations for 13 consecutive years, with 96213000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 27.75% year-over-year to 96213000.0, compared with a TTM value of 372977000.0 through Dec 2025, up 4.33%, and an annual FY2025 reading of 372977000.0, up 4.33% over the prior year.
  • Cash from Operations was 96213000.0 for Q4 2025 at Agios Pharmaceuticals, down from 88151000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 38480000.0 in Q2 2021 and bottomed at 163998000.0 in Q3 2021.
  • Average Cash from Operations over 5 years is 88783900.0, with a median of 84155500.0 recorded in 2021.
  • Peak annual rise in Cash from Operations hit 59.23% in 2021, while the deepest fall reached 734.6% in 2021.
  • Year by year, Cash from Operations stood at 84093000.0 in 2021, then grew by 21.32% to 66163000.0 in 2022, then dropped by 9.56% to 72488000.0 in 2023, then crashed by 83.71% to 133167000.0 in 2024, then rose by 27.75% to 96213000.0 in 2025.
  • Business Quant data shows Cash from Operations for AGIO at 96213000.0 in Q4 2025, 88151000.0 in Q3 2025, and 77124000.0 in Q2 2025.